FTC settles Hikma Roxane competition concerns

06-05-2016

FTC settles Hikma Roxane competition concerns

Felix Lipov / Shutterstock.com

The US Federal Trade Commission (FTC) has approved a final order settling charges that pharmaceutical company Hikma’s buyout of Roxane Laboratories and Boehringer Ingelheim Roxane would be anticompetitive.


FTC, acquisition, Hikma Pharmaceuticals, Roxane Laboratories, Tambocor, Boehringer Ingelheim Roxane,

LSIPR